Jaguar Health, Inc.
JAGXNASDAQHealthcare● Active
$2.84
+$0.11(+4.03%)
Market Cap$189258
P/E Ratio—
52W High$137.2
52W Low$2.53
Jaguar Health, Inc. (JAGX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JAGX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$13.60
Est. -$149.10 · +90.9%
Revenue
$0.00B
Est. $0.00B · -23.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
JAGX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$52.15 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 20, 2026 | -$149.10 | -$13.60 | +90.9% | $0.00B | $0.00B | -23.2% |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$71.40 | -$13.60 | +81.0% | $0.00B | $0.00B | -44.8% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$5.08 | -$6.28 | -23.6% | $0.00B | $0.00B | -17.4% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$7.13 | -$10.26 | -43.9% | $0.00B | $0.00B | -8.9% |
| ▼ Q2 FY2025 | May 15, 2025 | -$10.82 | -$16.70 | -54.3% | $0.00B | $0.00B | -21.5% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$18.50 | -$14.72 | +20.4% | $0.00B | $0.00B | +12.9% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$59.25 | -$26.25 | +55.7% | $0.00B | $0.00B | -21.4% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$52.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Beat
EPS Actual
-$13.60
EPS Est.
-$149.10
EPS Surpr.
+90.9%
Revenue
$0.00B
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$13.60
EPS Est.
-$71.40
EPS Surpr.
+81.0%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$6.28
EPS Est.
-$5.08
EPS Surpr.
-23.6%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$10.26
EPS Est.
-$7.13
EPS Surpr.
-43.9%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$16.70
EPS Est.
-$10.82
EPS Surpr.
-54.3%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$14.72
EPS Est.
-$18.50
EPS Surpr.
+20.4%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$26.25
EPS Est.
-$59.25
EPS Surpr.
+55.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-44.45 | $-44.45 | $-44.45 | 1 |
| Q3 FY2026 | $-40.95 | $-40.95 | $-40.95 | 1 |
| Q2 FY2026 | $-52.15 | $-52.15 | $-52.15 | 1 |
| Q1 FY2026 | $-71.40 | $-71.40 | $-71.40 | 1 |
| Q4 FY2025 | $-149.10 | $-149.10 | $-149.10 | 1 |
| Q3 FY2025 | $-177.80 | $-177.80 | $-177.80 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 20, 2026 | +90.9% | $3.36 | $3.67 | +9.23% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +81.0% | $11.99 | $11.66 | -2.75% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -23.6% | $59.50 | $62.30 | +4.71% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -43.9% | $90.65 | $72.45 | -20.08% |
| ▼ Q2 FY2025 | May 15, 2025 | -54.3% | $215.95 | $192.50 | -10.86% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +20.4% | $175.00 | $166.60 | -4.80% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +55.7% | $953.75 | $864.15 | -9.39% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -235.5% | $1,050.00 | $936.25 | -10.83% |
Q2 FY2026+9.23%
Report Date
May 20, 2026
EPS Beat/Miss
+90.9%
Price Before
$3.36
Price After
$3.67
Q1 FY2026-2.75%
Report Date
Mar 30, 2026
EPS Beat/Miss
+81.0%
Price Before
$11.99
Price After
$11.66
Q4 FY2025+4.71%
Report Date
Nov 14, 2025
EPS Beat/Miss
-23.6%
Price Before
$59.50
Price After
$62.30
Q3 FY2025-20.08%
Report Date
Aug 14, 2025
EPS Beat/Miss
-43.9%
Price Before
$90.65
Price After
$72.45
Q2 FY2025-10.86%
Report Date
May 15, 2025
EPS Beat/Miss
-54.3%
Price Before
$215.95
Price After
$192.50
Q1 FY2025-4.80%
Report Date
Mar 31, 2025
EPS Beat/Miss
+20.4%
Price Before
$175.00
Price After
$166.60
Q4 FY2024-9.39%
Report Date
Nov 13, 2024
EPS Beat/Miss
+55.7%
Price Before
$953.75
Price After
$864.15
Q3 FY2024-10.83%
Report Date
Aug 13, 2024
EPS Beat/Miss
-235.5%
Price Before
$1,050.00
Price After
$936.25
Avg Beat Reaction-1.93%
Avg Miss Reaction-9.26%
Beat Rate4 / 8 quarters
Largest Move-20.08% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JAGX ends December
Jaguar Health, Inc. (JAGX) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-13.60 — beating the analyst consensus of $-149.10 by +90.9%. JAGX has beaten EPS estimates for 2 consecutive quarters. The next JAGX earnings date is expected around September 1, 2026.
Each quarter, investors track JAGX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JAGX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JAGX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JAGX earnings · 5 questionsJaguar Health, Inc.'s next earnings report is expected around September 1, 2026. JAGX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JAGX historically reports after market close (AMC).
JAGX earnings datewhen is JAGX earningsJAGX next earnings datewhen does JAGX report earningsJAGX earnings calendar
▸ Source: FMP · Jaguar Health, Inc. SEC filings · US GAAP · Jaguar Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026